If IGFBP1 is acting beneficially, then by reducing the levels of hepatic oleic acid, either by dietary or pharmacological intervention, may be an effective form of treating HCD-induced obesity and the associated metabolic dysfunction. Here, IGFBP1 is linked to obesity disorder.